ONC
$386.49+0.52%
as of close, Oct 21, 2026
☾ AH $386.49 +0.52%
BeOne Medicines Ltd. American Depositary SharesStock · Healthcare
ONC SEC filings (2026)
CIK 1651308 · Pharmaceutical Preparations (SIC 2834) · fiscal year ends in December
1,265 filings on EDGAR since 2015 · 13 annual, 32 quarterly, 284 current · financial statements · earnings
Latest 10-K
Feb 26, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 5, 2026
quarter to Jun 30, 2026
Latest 8-K
Aug 26, 2026
Results of operations
Last earnings release
Aug 26, 2026
8-K, Item 2.02
Filings on file
1,265
since 2015, 715 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
September 2026
- Sep 30Insider saleLee Chan Henry (SVP, General Counsel) sold 1,115 ADS shares for $418K at $375.00 under a 10b5-1 plan
- Sep 28Insider saleWang Xiaodong (Director · Chair, Scientific Advisory Brd) sold 31,028 ADS shares for $11.3M at $356.97–$367.23 under a 10b5-1 plan
- Sep 8Insider saleWang Xiaodong (Director · Chair, Scientific Advisory Brd) sold 38,287 ADS shares for $13.4M at $345.38–$351.25 under a 10b5-1 plan
- Sep 1Insider saleBall Titus B. (Principal Accounting Officer) sold 132 ADS shares for $47K at $355.86
August 2026
- Aug 268-K8-K · Results of operations
- Aug 25Insider saleWu Xiaobin (President and COO) sold 280 ADS shares for $106K at $380.00 under a 10b5-1 plan
- Aug 12Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 54,892 ADS shares for $19.7M at $354.71–$359.12 under a 10b5-1 plan
- Aug 11Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 70,907 ADS shares for $25.7M at $359.32–$367.00 under a 10b5-1 plan
- Aug 11Insider saleLee Chan Henry (SVP, General Counsel) sold 2,666 ADS shares for $960K at $360.00 under a 10b5-1 plan
- Aug 10Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 115,011 ADS shares for $41.2M at $350.00–$360.63 under a 10b5-1 plan
- Aug 5EarningsEarnings release — EPS $2.05 vs $1.40 est. (+46.4%); revenue $1.71B (+30% y/y) 1.4%
- Aug 5ReportQuarterly report, Q2 2026 — revenue $1.71B (+30% y/y), net income $237.0M, EPS $2.08
- Aug 3Insider saleRosenberg Aaron (Chief Financial Officer) sold 1,157 ADS shares for $362K at $312.72
July 2026
- Jul 30Insider saleLee Chan Henry (SVP, General Counsel) sold 1,044 ADS shares for $338K at $323.69
- Jul 22Insider saleLee Chan Henry (SVP, General Counsel) sold 1,669 ADS shares for $542K at $325.00 under a 10b5-1 plan
- Jul 21Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 61,397 ADS shares for $19.5M at $316.26–$320.06 under a 10b5-1 plan
- Jul 20Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 48,316 ADS shares for $15.1M at $310.08–$318.30 under a 10b5-1 plan
- Jul 17Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 64,628 ADS shares for $20.2M at $305.20–$315.06 under a 10b5-1 plan
- Jul 16Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 166,597 ADS shares for $53.0M at $311.98–$323.59 under a 10b5-1 plan
- Jul 15Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 116,557 ADS shares for $36.4M at $310.02–$313.58 under a 10b5-1 plan
- Jul 14Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 145,861 ADS shares for $44.6M at $303.07–$307.57 under a 10b5-1 plan
- Jul 13Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 48,520 ADS shares for $14.8M at $301.94–$307.41 under a 10b5-1 plan
- Jul 10Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 11,698 ADS shares for $3.5M at $296.07–$303.03 under a 10b5-1 plan
- Jul 8Insider saleLee Chan Henry (SVP, General Counsel) sold 664 ADS shares for $201K at $302.46 under a 10b5-1 plan
June 2026
- Jun 268-K8-K · Other events
- Jun 23Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 3,410 ADS shares for $934K at $273.30–$275.10
- Jun 23Insider saleWu Xiaobin (President and COO) sold 1,292 ADS shares for $357K at $276.26
- Jun 23Insider saleWang Lai (President, Global Head of R&D) sold 1,068 ADS shares for $296K at $276.74
- Jun 16Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 3,693 ADS shares for $981K at $264.87–$266.69
- Jun 16Insider saleWu Xiaobin (President and COO) sold 1,357 ADS shares for $362K at $266.76
- Jun 16Insider saleWang Lai (President, Global Head of R&D) sold 1,169 ADS shares for $310K at $265.39
- Jun 16Insider saleLee Chan Henry (SVP, General Counsel) sold 590 ADS shares for $157K at $265.98
- Jun 11Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 1,949 ADS shares for $501K at $256.23–$258.81
- Jun 11Insider saleWang Lai (President, Global Head of R&D) sold 756 ADS shares for $197K at $261.00
- Jun 11Insider saleWu Xiaobin (President and COO) sold 626 ADS shares for $164K at $261.20
- Jun 11Insider saleRosenberg Aaron (Chief Financial Officer) sold 631 ADS shares for $163K at $257.74
- Jun 11Insider saleLee Chan Henry (SVP, General Counsel) sold 428 ADS shares for $110K at $257.64
- Jun 11Insider saleBall Titus B. (Principal Accounting Officer) sold 169 ADS shares for $43K at $256.39–$257.53
- Jun 118-K8-K · Directors or officers; compensation; Shareholder vote results
- Jun 8Insider saleOYLER JOHN (Chief Executive Officer · Director) sold 4,940 ADS shares for $1.3M at $270.38–$271.14
- Jun 8Insider saleWu Xiaobin (President and COO) sold 1,484 ADS shares for $400K at $269.33–$270.55
- Jun 8Insider saleWang Lai (President, Global Head of R&D) sold 1,367 ADS shares for $368K at $269.34–$270.73
- Jun 8Insider saleLee Chan Henry (SVP, General Counsel) sold 871 ADS shares for $236K at $270.24–$271.26
- Jun 8Insider saleBall Titus B. (Principal Accounting Officer) sold 136 ADS shares for $37K at $271.06–$272.08
- Jun 1Insider saleYi Qingqing (Director) sold 235 ADS shares for $66K at $279.13
May 2026
- May 22Insider saleBAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN (6 filers) sold 10,998 shares for $262K at $23.79–$23.85
- May 22Insider saleDugan Margaret (Director) sold 212 ADS shares for $66K at $309.60
- May 22Insider saleSanders Corazon (Corsee) D. (Director) sold 212 ADS shares for $66K at $309.59
- May 22Insider saleRiva Alessandro (Director) sold 212 ADS shares for $66K at $309.51
- May 158-K8-K · BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell LymphomaOther events
- May 13Insider saleLee Chan Henry (SVP, General Counsel) sold 332 ADS shares for $103K at $310.72 under a 10b5-1 plan
- May 6EarningsEarnings release — EPS $1.96 vs $0.73 est. (+168.5%); revenue $1.51B (+35% y/y) 5.3%
- May 6ReportQuarterly report, Q1 2026 — revenue $1.51B (+35% y/y), net income $227.4M, EPS $1.95
April 2026
- Apr 28ProxyProxy · Annual report to shareholders
- Apr 28ProxyProxy · Additional proxy materials
- Apr 28ProxyProxy · Proxy statement
- Apr 16ProxyProxy · Preliminary proxy statement
- Apr 148-K8-K · Results of operations
- Apr 8Insider saleLee Chan Henry (SVP, General Counsel) sold 332 ADS shares for $103K at $311.59 under a 10b5-1 plan
March 2026
February 2026
- Feb 26EarningsEarnings release — EPS $0.58 vs $1.60 est. (−63.8%); revenue $1.50B (+33% y/y) 8.5%
- Feb 26ReportAnnual report, FY2025 — revenue $5.34B (+40% y/y), net income $286.9M, EPS $2.47
- Feb 4Insider saleLee Chan Henry (SVP, General Counsel) sold 1,660 ADS shares for $580K at $348.79–$350.00 under a 10b5-1 plan
January 2026
December 2025
- Dec 198-K8-K · Termination of a material agreement
- Dec 188-K8-K · Directors or officers; compensation
November 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $340.6M in 50 sales and bought nothing on the open market; 65 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Oct 13, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdSold · ADS · $10.9M · 31,027 sh · 10b5-1 |
| Sep 30, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $418K · 1,115 sh · 10b5-1 |
| Sep 28, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdSold · ADS · $11.3M · 31,028 sh · 10b5-1 |
| Sep 8, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdSold · ADS · $13.4M · 38,287 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Ball Titus B.Principal Accounting OfficerSold · ADS · $47K · 132 sh |
| Aug 25, 2026Form 4 | Wu XiaobinPresident and COOSold · ADS · $106K · 280 sh · 10b5-1 |
| Aug 12, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $19.7M · 54,892 sh · 10b5-1 |
| Aug 11, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $25.7M · 70,907 sh · 10b5-1 |
| Aug 11, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $960K · 2,666 sh · 10b5-1 |
| Aug 10, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $41.2M · 115,011 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Rosenberg AaronChief Financial OfficerSold · ADS · $362K · 1,157 sh |
| Jul 30, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $338K · 1,044 sh |
| Jul 22, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $542K · 1,669 sh · 10b5-1 |
| Jul 21, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $19.5M · 61,397 sh · 10b5-1 |
| Jul 20, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $15.1M · 48,316 sh · 10b5-1 |
| Jul 17, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $20.2M · 64,628 sh · 10b5-1 |
| Jul 16, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $53.0M · 166,597 sh · 10b5-1 |
| Jul 15, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $36.4M · 116,557 sh · 10b5-1 |
| Jul 14, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $44.6M · 145,861 sh · 10b5-1 |
| Jul 13, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $14.8M · 48,520 sh · 10b5-1 |
| Jul 10, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $3.5M · 11,698 sh · 10b5-1 |
| Jul 8, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $201K · 664 sh · 10b5-1 |
| Jun 23, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $934K · 3,410 sh |
| Jun 23, 2026Form 4 | Wu XiaobinPresident and COOSold · ADS · $357K · 1,292 sh |
| Jun 23, 2026Form 4 | Wang LaiPresident, Global Head of R&DSold · ADS · $296K · 1,068 sh |
| Jun 16, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $981K · 3,693 sh |
| Jun 16, 2026Form 4 | Wu XiaobinPresident and COOSold · ADS · $362K · 1,357 sh |
| Jun 16, 2026Form 4 | Wang LaiPresident, Global Head of R&DSold · ADS · $310K · 1,169 sh |
| Jun 16, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $157K · 590 sh |
| Jun 11, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $501K · 1,949 sh |
| Jun 11, 2026Form 4 | Wang LaiPresident, Global Head of R&DSold · ADS · $197K · 756 sh |
| Jun 11, 2026Form 4 | Wu XiaobinPresident and COOSold · ADS · $164K · 626 sh |
| Jun 11, 2026Form 4 | Rosenberg AaronChief Financial OfficerSold · ADS · $163K · 631 sh |
| Jun 11, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $110K · 428 sh |
| Jun 11, 2026Form 4 | Ball Titus B.Principal Accounting OfficerSold · ADS · $43K · 169 sh |
| Jun 8, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorSold · ADS · $1.3M · 4,940 sh |
| Jun 8, 2026Form 4 | Wu XiaobinPresident and COOSold · ADS · $400K · 1,484 sh |
| Jun 8, 2026Form 4 | Wang LaiPresident, Global Head of R&DSold · ADS · $368K · 1,367 sh |
| Jun 8, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $236K · 871 sh |
| Jun 8, 2026Form 4 | Ball Titus B.Principal Accounting OfficerSold · ADS · $37K · 136 sh |
| Jun 1, 2026Form 4 | Yi QingqingDirectorSold · ADS · $66K · 235 sh |
| May 22, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersSold · $262K · 10,998 sh |
| May 22, 2026Form 4 | Dugan MargaretDirectorSold · ADS · $66K · 212 sh |
| May 22, 2026Form 4 | Sanders Corazon (Corsee) D.DirectorSold · ADS · $66K · 212 sh |
| May 22, 2026Form 4 | Riva AlessandroDirectorSold · ADS · $66K · 212 sh |
| May 13, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $103K · 332 sh · 10b5-1 |
| Apr 8, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $103K · 332 sh · 10b5-1 |
| Mar 11, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $102K · 341 sh · 10b5-1 |
| Feb 4, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $580K · 1,660 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Lee Chan HenrySVP, General CounselSold · ADS · $220K · 664 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 65 transactions
| Date | Insider |
|---|---|
| Oct 13, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdExercise or conversion · ADS · $1.1M · 31,027 sh · 10b5-1 |
| Oct 13, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdExercise or conversion · Share Option (Right to Buy) · $0 · 403,351 sh · 10b5-1 |
| Sep 28, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdExercise or conversion · ADS · $1.1M · 31,028 sh · 10b5-1 |
| Sep 28, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdExercise or conversion · Share Option (Right to Buy) · $0 · 403,364 sh · 10b5-1 |
| Sep 14, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersExercise or conversion · ADS · $2.3M · 61,536 sh |
| Sep 14, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersExercise or conversion · Non-Qualified Share Options · $0 · 61,536 sh |
| Sep 8, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdExercise or conversion · ADS · $1.1M · 31,027 sh · 10b5-1 |
| Sep 8, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdExercise or conversion · Share Option (Right to Buy) · $0 · 403,351 sh · 10b5-1 |
| Aug 11, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · ADS · $510K · 2,666 sh · 10b5-1 |
| Aug 11, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · Share Option (Right to Buy) · $0 · 34,658 sh · 10b5-1 |
| Jul 22, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · ADS · $320K · 1,669 sh · 10b5-1 |
| Jul 22, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · Share Option (Right to Buy) · $0 · 21,697 sh · 10b5-1 |
| Jul 20, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · ADS · $4.1M · 33,990 sh · 10b5-1 |
| Jul 20, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · Share Option (Right to Buy) · $0 · 441,870 sh · 10b5-1 |
| Jul 17, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · ADS · $7.8M · 64,628 sh · 10b5-1 |
| Jul 17, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · Share Option (Right to Buy) · $0 · 840,164 sh · 10b5-1 |
| Jul 16, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · ADS · $23.9M · 166,597 sh · 10b5-1 |
| Jul 16, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · Share Option (Right to Buy) · $0 · 2,165,761 sh · 10b5-1 |
| Jul 15, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · ADS · $17.3M · 116,557 sh · 10b5-1 |
| Jul 15, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · Share Option (Right to Buy) · $0 · 1,515,241 sh · 10b5-1 |
| Jul 14, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · ADS · $7.2M · 133,600 sh · 10b5-1 |
| Jul 14, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · Share Option (Right to Buy) · $0 · 1,736,800 sh · 10b5-1 |
| Jul 13, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · ADS · $1.8M · 48,520 sh · 10b5-1 |
| Jul 13, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · Share Option (Right to Buy) · $0 · 630,760 sh · 10b5-1 |
| Jul 10, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · ADS · $432K · 11,698 sh · 10b5-1 |
| Jul 10, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorExercise or conversion · Share Option (Right to Buy) · $0 · 152,074 sh · 10b5-1 |
| Jul 8, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · ADS · $127K · 664 sh · 10b5-1 |
| Jul 8, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · Share Option (Right to Buy) · $0 · 8,632 sh · 10b5-1 |
| Jun 11, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorAward · Share Option (Right to Buy) · $0 · 344,669 sh |
| Jun 11, 2026Form 4 | Wu XiaobinPresident and COOAward · Share Option (Right to Buy) · $0 · 229,775 sh |
| Jun 11, 2026Form 4 | Wang LaiPresident, Global Head of R&DAward · Share Option (Right to Buy) · $0 · 229,775 sh |
| Jun 11, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdAward · Share Option (Right to Buy) · $0 · 193,492 sh |
| Jun 11, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorAward · $0 · 177,931 sh |
| Jun 11, 2026Form 4 | Rosenberg AaronChief Financial OfficerAward · Share Option (Right to Buy) · $0 · 137,865 sh |
| Jun 11, 2026Form 4 | Wu XiaobinPresident and COOAward · $0 · 118,625 sh |
| Jun 11, 2026Form 4 | Wang LaiPresident, Global Head of R&DAward · $0 · 118,625 sh |
| Jun 11, 2026Form 4 | Wang XiaodongDirector · Chair, Scientific Advisory BrdAward · $0 · 99,892 sh |
| Jun 11, 2026Form 4 | Lee Chan HenrySVP, General CounselAward · Share Option (Right to Buy) · $0 · 87,308 sh |
| Jun 11, 2026Form 4 | Rosenberg AaronChief Financial OfficerAward · $0 · 71,175 sh |
| Jun 11, 2026Form 4 | Lee Chan HenrySVP, General CounselAward · $0 · 45,071 sh |
| Jun 11, 2026Form 4 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 37,960 sh |
| Jun 11, 2026Form 4 | Ball Titus B.Principal Accounting OfficerAward · $0 · 31,213 sh |
| Jun 11, 2026Form 4 | HOOPER ANTHONY CDirectorAward · $0 · 18,980 sh |
| Jun 11, 2026Form 4 | Sharp ShaliniDirectorAward · $0 · 18,980 sh |
| Jun 11, 2026Form 4 | BRANDICOURT OLIVIERDirectorAward · $0 · 18,980 sh |
| Jun 11, 2026Form 4 | Riva AlessandroDirectorAward · $0 · 18,980 sh |
| Jun 11, 2026Form 4 | Dugan MargaretDirectorAward · $0 · 18,980 sh |
| Jun 11, 2026Form 4 | Sawyers Charles LazelleDirectorAward · $0 · 18,980 sh |
| Jun 11, 2026Form 4 | Mooney Elizabeth FisherDirectorAward · $0 · 18,980 sh |
| May 13, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · ADS · $64K · 332 sh · 10b5-1 |
| May 13, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · Share Option (Right to Buy) · $0 · 4,316 sh · 10b5-1 |
| Apr 8, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · ADS · $64K · 332 sh · 10b5-1 |
| Apr 8, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · Share Option (Right to Buy) · $0 · 4,316 sh · 10b5-1 |
| Mar 11, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · ADS · $65K · 341 sh · 10b5-1 |
| Mar 11, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · Share Option (Right to Buy) · $0 · 4,433 sh · 10b5-1 |
| Mar 6, 2026Form 4 | OYLER JOHNChief Executive Officer · DirectorAward · $0 · 444,912 sh |
| Mar 6, 2026Form 4 | Wu XiaobinPresident and COOAward · $0 · 247,546 sh |
| Mar 6, 2026Form 4 | Wang LaiPresident, Global Head of R&DAward · $0 · 167,635 sh |
| Mar 6, 2026Form 4 | Rosenberg AaronChief Financial OfficerAward · $0 · 119,587 sh |
| Mar 6, 2026Form 4 | Lee Chan HenrySVP, General CounselAward · $0 · 95,264 sh |
| Feb 4, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · ADS · $318K · 1,660 sh · 10b5-1 |
| Feb 4, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · Share Option (Right to Buy) · $0 · 21,580 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · ADS · $127K · 664 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Lee Chan HenrySVP, General CounselExercise or conversion · Share Option (Right to Buy) · $0 · 8,632 sh · 10b5-1 |
| Dec 31, 2025Form 4 | Wang LaiPresident, Global Head of R&DAward · $0 · 427,895 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 15 filings
| Filed | What it is |
|---|---|
| Aug 26, 20268-K | Results of operations |
| Aug 5, 202610-Q | Quarterly report, Q2 2026 — revenue $1.71B (+30% y/y), net income $237.0M, EPS $2.08 |
| Aug 5, 20268-K | Earnings release — EPS $2.05 vs $1.40 est. (+46.4%); revenue $1.71B (+30% y/y) 1.4% |
| Jun 26, 20268-K | Other events |
| Jun 11, 20268-K | Directors or officers; compensation; Shareholder vote results |
| May 15, 20268-K | BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell LymphomaOther events |
| May 6, 202610-Q | Quarterly report, Q1 2026 — revenue $1.51B (+35% y/y), net income $227.4M, EPS $1.95 |
| May 6, 20268-K | Earnings release — EPS $1.96 vs $0.73 est. (+168.5%); revenue $1.51B (+35% y/y) 5.3% |
| Apr 28, 2026ARS | Annual report to shareholders |
| Apr 28, 2026DEFA14A | Additional proxy materials |
| Apr 28, 2026DEF 14A | Proxy statement |
| Apr 16, 2026PRE 14A | Preliminary proxy statement |
| Apr 14, 20268-K | Results of operations |
| Feb 26, 202610-K | Annual report, FY2025 — revenue $5.34B (+40% y/y), net income $286.9M, EPS $2.47 |
| Feb 26, 20268-K | Earnings release — EPS $0.58 vs $1.60 est. (−63.8%); revenue $1.50B (+33% y/y) 8.5% |
2025 · 26 filings
| Filed | What it is |
|---|---|
| Dec 19, 20258-K | Termination of a material agreement |
| Dec 18, 20258-K | Directors or officers; compensation |
| Nov 19, 20258-K | Material definitive agreement; New financial obligation |
| Nov 6, 202510-Q | Quarterly report, Q3 2025 — revenue $1.41B (+41% y/y), net income $124.8M, EPS $1.04 |
| Nov 6, 20258-K | Earnings release — EPS $1.09 vs $0.72 est. (+51.4%); revenue $1.41B (+41% y/y) 3.4% |
| Aug 29, 20258-K | Results of operations |
| Aug 25, 20258-K | Material definitive agreement; New financial obligation; Regulation FD disclosure |
| Aug 6, 202510-Q | Quarterly report, Q2 2025 — revenue $1.32B (+42% y/y), net income $94.3M, EPS $0.78 |
| Aug 6, 20258-K | Earnings release — EPS $0.84 vs $0.48 est. (+75.0%); revenue $1.32B (+42% y/y) 2.8% |
| May 21, 20258-K | Shareholder vote results |
| May 13, 20258-K | Unregistered sale of equity |
| May 7, 202510-Q | Quarterly report, Q1 2025 — revenue $1.12B (+49% y/y), net income $1.3M, EPS $0.00 |
| May 7, 20258-K | Earnings release — EPS $1.22 vs −$0.71 est. (+271.8%); revenue $1.12B (+49% y/y) 3.9% |
| Apr 29, 20258-K | Other events |
| Apr 28, 20258-K | Shareholder vote results |
| Apr 28, 20258-K | Results of operations |
| Apr 7, 2025ARS | Annual report to shareholders |
| Apr 7, 2025DEFA14A | Additional proxy materials |
| Apr 7, 2025DEF 14A | Proxy statement |
| Mar 27, 2025PRE 14A | Preliminary proxy statement |
| Mar 10, 2025DEFA14A | Additional proxy materials |
| Feb 28, 202510-K/A | Annual report, amended |
| Feb 27, 202510-K | Annual report, FY2024 — revenue $3.81B (+55% y/y), net income −$644.8M, EPS −$6.11 |
| Feb 27, 20258-K | Earnings release — EPS −$1.43 vs −$0.88 est. (−62.5%); revenue $1.13B (+78% y/y) 7.5% |
| Jan 13, 20258-K | Regulation FD disclosure |
| Jan 8, 202510-K/A | Annual report, amended |
2024 · 27 filings
| Filed | What it is |
|---|---|
| Dec 23, 20248-K | Other events |
| Dec 10, 20248-K | Material definitive agreement; New financial obligation |
| Nov 19, 20248-K | Other events |
| Nov 14, 20248-K | Other events |
| Nov 12, 202410-Q | Quarterly report, Q3 2024 — revenue $1.00B (+28% y/y), net income −$121.3M, EPS −$1.17 |
| Nov 12, 20248-K | Earnings release — EPS −$1.15 vs −$0.88 est. (−30.7%); revenue $1.00B (+28% y/y) 5.6% |
| Oct 28, 20248-K | Other events |
| Sep 30, 20248-K | Other events |
| Sep 26, 20248-K | Directors or officers; compensation |
| Aug 29, 20248-K | Results of operations |
| Aug 7, 202410-Q | Quarterly report, Q2 2024 — revenue $929.2M (+56% y/y), net income −$120.4M, EPS −$1.17 |
| Aug 7, 20248-K | Earnings release — EPS −$1.15 vs −$2.10 est. (+45.2%); revenue $929.2M (+56% y/y) 3.2% |
| Jul 18, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| Jun 5, 20248-K | Directors or officers; compensation; Shareholder vote results |
| May 8, 202410-Q | Quarterly report, Q1 2024 — revenue $751.7M (+68% y/y), net income −$251.2M, EPS −$2.47 |
| May 8, 20248-K | Earnings release — EPS −$2.41 vs −$2.98 est. (+19.1%); revenue $751.7M (+68% y/y) 2.4% |
| Apr 26, 2024ARS | Annual report to shareholders |
| Apr 26, 2024DEF 14A | Proxy statement |
| Apr 26, 20248-K | Results of operations |
| Apr 23, 20248-K | Other events |
| Apr 15, 2024PRE 14A | Preliminary proxy statement |
| Mar 20, 20248-K | Directors or officers; compensation; Other events |
| Mar 15, 20248-K | Other events |
| Mar 8, 20248-K | Other events |
| Feb 26, 202410-K | Annual report, FY2023 — revenue $2.46B (+74% y/y), net income −$881.7M, EPS −$8.45 |
| Feb 26, 20248-K | Earnings release — EPS −$3.53 vs −$2.36 est. (−49.6%); revenue $634.4M (+67% y/y) 3.3% |
| Jan 23, 20248-K | Directors or officers; compensation |
2023 · 27 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 9, 202310-Q | Quarterly report, Q3 2023 — revenue $781.3M (+102% y/y), net income $215.4M, EPS $1.95 |
| Aug 2, 202310-Q | Quarterly report, Q2 2023 — revenue $595.3M (+74% y/y), net income −$381.1M, EPS −$3.64 |
| May 4, 202310-Q | Quarterly report, Q1 2023 — revenue $447.8M (+46% y/y), net income −$348.4M, EPS −$3.38 |
| Apr 27, 2023ARS | Annual report to shareholders |
| Apr 27, 2023DEF 14A | Proxy statement |
| Apr 17, 2023PRE 14A | Preliminary proxy statement |
| Feb 27, 202310-K | Annual report, FY2022 — revenue $1.42B (+20% y/y), net income −$2.00B, EPS −$19.37 |
20 current reports (8-K) not listed; the year is on EDGAR.
2022 · 36 filings — 30 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 9, 202210-Q | Quarterly report, Q3 2022 — revenue $387.6M (+88% y/y), net income −$557.6M, EPS −$5.33 |
| Aug 8, 202210-Q | Quarterly report, Q2 2022 — revenue $341.6M (+128% y/y), net income −$565.7M, EPS −$5.46 |
| May 9, 202210-Q | Quarterly report, Q1 2022 — revenue $306.6M (−49% y/y), net income −$435.2M, EPS −$4.29 |
| Apr 29, 2022DEF 14A | Proxy statement |
| Apr 18, 2022PRE 14A | Preliminary proxy statement |
| Feb 28, 202210-K | Annual report, FY2021 — revenue $1.18B (+281% y/y), net income −$1.46B, EPS −$15.73 |
30 current reports (8-K) not listed; the year is on EDGAR.
2021 · 58 filings — 51 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 4, 202110-Q | Quarterly report, Q3 2021 — revenue $206.4M (+127% y/y), net income −$438.1M, EPS −$4.68 |
| Aug 5, 202110-Q | Quarterly report, Q2 2021 — revenue $150.0M (+129% y/y), net income −$480.3M, EPS −$5.20 |
| May 6, 202110-Q | Quarterly report, Q1 2021 — revenue $605.9M (+1064% y/y), net income $66.5M, EPS $0.65 |
| Apr 30, 2021DEF 14A | Proxy statement |
| Apr 19, 2021PRE 14A | Preliminary proxy statement |
| Feb 25, 202110-K | Annual report, FY2020 — revenue $308.9M (−28% y/y), net income −$1.62B, EPS −$19.50 |
| Jan 29, 2021DEFA14A | Additional proxy materials |
51 current reports (8-K) not listed; the year is on EDGAR.
2020 · 44 filings — 35 × 8-K, 3 × 10-Q, 2 × DEF 14A and 3 other forms
| Filed | What it is |
|---|---|
| Nov 5, 202010-Q | Quarterly report, Q3 2020 — revenue $91.1M (+82% y/y), net income −$425.2M |
| Oct 9, 2020DEF 14A | Proxy statement |
| Sep 28, 2020PRER14A | Proxy statements |
| Aug 6, 202010-Q | Quarterly report, Q2 2020 — revenue $65.6M (−73% y/y), net income −$335.2M |
| May 11, 202010-Q | Quarterly report, Q1 2020 — revenue $52.1M (−33% y/y), net income −$363.7M, EPS −$4.68 |
| Apr 28, 2020DEF 14A | Proxy statement |
| Apr 17, 2020PRE 14A | Preliminary proxy statement |
| Mar 30, 2020PRE 14A | Preliminary proxy statement |
| Mar 2, 202010-K | Annual report, FY2019 — revenue $428.2M (+116% y/y), net income −$948.6M, EPS −$15.86 |
35 current reports (8-K) not listed; the year is on EDGAR.
2019 · 38 filings — 28 × 8-K, 3 × 10-Q, 2 × DEF 14A and 4 other forms
| Filed | What it is |
|---|---|
| Dec 6, 2019DEFA14A | Additional proxy materials |
| Nov 29, 2019DEF 14A | Proxy statement |
| Nov 19, 2019PRE 14A | Preliminary proxy statement |
| Nov 12, 201910-Q | Quarterly report, Q3 2019 — revenue $50.1M (−7% y/y), net income −$307.4M |
| Aug 8, 201910-Q | Quarterly report, Q2 2019 — revenue $243.3M (+361% y/y), net income −$85.6M |
| May 9, 201910-Q | Quarterly report, Q1 2019 — revenue $77.8M (+139% y/y), net income −$167.6M |
| Apr 29, 2019DEF 14A | Proxy statement |
| Apr 11, 2019PRE 14A | Preliminary proxy statement |
| Feb 28, 201910-K | Annual report, FY2018 — revenue $198.2M (−17% y/y), net income −$673.8M |
29 current reports (8-K) not listed; the year is on EDGAR.
2018 · 43 filings — 36 × 8-K, 3 × 10-Q, 2 × DEF 14A and 2 other forms
| Filed | What it is |
|---|---|
| Nov 8, 2018DEF 14A | Proxy statement |
| Nov 8, 201810-Q | Quarterly report, Q3 2018 — revenue $54.2M (−75% y/y), net income −$144.0M, EPS −$2.47 |
| Oct 19, 2018PRE 14A | Preliminary proxy statement |
| Aug 9, 201810-Q | Quarterly report, Q2 2018 — revenue $52.8M, net income −$156.9M |
| May 9, 201810-Q | Quarterly report, Q1 2018 — revenue $32.5M, net income −$104.6M |
| Apr 30, 2018DEF 14A | Proxy statement |
| Feb 28, 201810-K | Annual report, FY2017 — revenue $238.4M (+22179% y/y), net income −$93.1M |
36 current reports (8-K) not listed; the year is on EDGAR.
2017 · 30 filings — 25 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 13, 201710-Q | Quarterly report, Q3 2017 — revenue $220.2M, net income $117.4M, EPS $2.60 |
| Aug 9, 201710-Q | Quarterly report, Q2 2017 — revenue $0 (−100% y/y), net income −$60.5M, EPS −$1.56 |
| May 10, 201710-Q | Quarterly report, Q1 2017 — revenue $0 (−100% y/y), net income −$50.6M, EPS −$1.30 |
| Apr 26, 2017DEF 14A | Proxy statement |
| Mar 22, 201710-K | Annual report, FY2016 — revenue $1.1M (−88% y/y), net income −$119.2M |
25 current reports (8-K) not listed; the year is on EDGAR.
2016 · 19 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 111 filings — 61 × 4, 40 × 144, 3 × SCHEDULE 13D/A and 5 other forms
| Filed | What it is |
|---|---|
| Oct 15, 20264 | Insider transaction (Form 4) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Sep 30, 20264 | Insider transaction (Form 4) |
| Sep 30, 2026144 | Notice of proposed sale (Form 144) |
| Sep 16, 2026SCHEDULE 13D/A | Other filings |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 10, 20264 | Insider transaction (Form 4) |
| Sep 8, 2026144 | Notice of proposed sale (Form 144) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 1, 2026144 | Notice of proposed sale (Form 144) |
| Aug 27, 20264 | Insider transaction (Form 4) |
| Aug 25, 2026144 | Notice of proposed sale (Form 144) |
| Aug 25, 2026144 | Notice of proposed sale (Form 144) |
| Aug 13, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 11, 2026144 | Notice of proposed sale (Form 144) |
| Aug 10, 2026144 | Notice of proposed sale (Form 144) |
| Aug 5, 20264 | Insider transaction (Form 4) |
| Aug 3, 20264 | Insider transaction (Form 4) |
| Aug 3, 2026144 | Notice of proposed sale (Form 144) |
| Jul 30, 2026144 | Notice of proposed sale (Form 144) |
| Jul 24, 20264 | Insider transaction (Form 4) |
| Jul 22, 20264 | Insider transaction (Form 4) |
| Jul 22, 2026144 | Notice of proposed sale (Form 144) |
| Jul 17, 20264 | Insider transaction (Form 4) |
The newest 25 of 111 shown; the full year is on EDGAR.
2025 · 157 filings — 74 × 4, 51 × 144, 9 × S-8 POS and 13 other forms
| Filed | What it is |
|---|---|
| Dec 17, 20254 | Insider transaction (Form 4) |
| Dec 15, 2025144 | Notice of proposed sale (Form 144) |
| Dec 12, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Nov 26, 2025144 | Notice of proposed sale (Form 144) |
| Nov 19, 20254 | Insider transaction (Form 4) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 20254 | Insider transaction (Form 4) |
| Nov 14, 20254 | Insider transaction (Form 4) |
| Nov 13, 20254 | Insider transaction (Form 4) |
| Nov 13, 2025144 | Notice of proposed sale (Form 144) |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
| Nov 12, 20254 | Insider transaction (Form 4) |
| Oct 10, 20254 | Insider transaction (Form 4) |
| Oct 8, 2025144 | Notice of proposed sale (Form 144) |
| Sep 18, 20254 | Insider transaction (Form 4) |
| Sep 16, 2025144 | Notice of proposed sale (Form 144) |
| Sep 16, 2025144 | Notice of proposed sale (Form 144) |
| Sep 12, 20254 | Insider transaction (Form 4) |
| Sep 11, 20254 | Insider transaction (Form 4) |
| Sep 11, 20254 | Insider transaction (Form 4) |
| Sep 10, 2025144 | Notice of proposed sale (Form 144) |
| Sep 9, 20254 | Insider transaction (Form 4) |
| Sep 9, 2025144 | Notice of proposed sale (Form 144) |
| Sep 5, 2025144 | Notice of proposed sale (Form 144) |
The newest 25 of 157 shown; the full year is on EDGAR.
2024 · 98 filings — 46 × 4, 33 × 144, 4 × 3 and 7 other forms
| Filed | What it is |
|---|---|
| Dec 17, 20244 | Insider transaction (Form 4) |
| Dec 12, 20244 | Insider transaction (Form 4) |
| Dec 10, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Dec 10, 20244 | Insider transaction (Form 4) |
| Dec 10, 20244 | Insider transaction (Form 4) |
| Dec 10, 2024144 | Notice of proposed sale (Form 144) |
| Dec 9, 2024144 | Notice of proposed sale (Form 144) |
| Dec 9, 2024144 | Notice of proposed sale (Form 144) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 4, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Dec 2, 2024144 | Notice of proposed sale (Form 144) |
| Nov 29, 20244 | Insider transaction (Form 4) |
| Nov 26, 2024144 | Notice of proposed sale (Form 144) |
| Nov 26, 2024144 | Notice of proposed sale (Form 144) |
| Nov 25, 2024144 | Notice of proposed sale (Form 144) |
| Oct 31, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Oct 31, 2024SCHEDULE 13D/A | Other filings |
| Oct 24, 2024CORRESP | Letter to the SEC |
| Oct 18, 2024UPLOAD | Letter from the SEC staff |
| Oct 10, 20244 | Insider transaction (Form 4) |
| Oct 8, 2024144 | Notice of proposed sale (Form 144) |
| Oct 8, 2024144 | Notice of proposed sale (Form 144) |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Oct 2, 20243 | Initial insider holdings (Form 3) |
| Oct 2, 20244 | Insider transaction (Form 4) |
The newest 25 of 98 shown; the full year is on EDGAR.
2023 · 64 filings — 33 × 4, 16 × 144, 3 × CORRESP and 5 other forms
Counted, not listed; the year is on EDGAR.
2022 · 52 filings — 35 × 4, 4 × SC 13G/A, 4 × UPLOAD and 6 other forms
Counted, not listed; the year is on EDGAR.
2021 · 78 filings — 61 × 4, 5 × CORRESP, 4 × UPLOAD and 4 other forms
Counted, not listed; the year is on EDGAR.
2020 · 102 filings — 80 × 4, 5 × 3, 5 × SC 13D/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2019 · 51 filings — 44 × 4, 3 × SC 13D/A, 2 × SC 13G/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2018 · 52 filings — 32 × 4, 4 × 424B5, 3 × 3 and 8 other forms
Counted, not listed; the year is on EDGAR.
2017 · 52 filings — 39 × 4, 2 × 424B5, 2 × S-3ASR and 7 other forms
Counted, not listed; the year is on EDGAR.
2016 · 77 filings — 23 × 4, 20 × 3, 7 × CORRESP and 15 other forms
Counted, not listed; the year is on EDGAR.
2015 · 8 filings — 2 × CORRESP, 2 × UPLOAD, 1 × DRS and 3 other forms
Counted, not listed; the year is on EDGAR.
About this data#
BeOne Medicines Ltd. American Depositary Shares (ONC) has 1,265 filings on EDGAR going back to 2015: 13 annual reports, 32 quarterly reports and 284 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 26, 2026, covered results of operations. Over the last 13 months insiders sold $340.6M in 50 sales and bought nothing on the open market; 65 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been BeOne Medicines Ltd. American Depositary Shares, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read ONC's latest 10-K?
- ONC's latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did ONC last file an 8-K?
- On Aug 26, 2026 it covered results of operations. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 26, 2026.
- Are ONC insiders buying or selling?
- Over the last 13 months insiders sold $340.6M in 50 sales and bought nothing on the open market; 65 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Wang Xiaodong (Director · Chair, Scientific Advisory Brd) sold 31,027 shares on Oct 13, 2026 for $10.9M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has ONC made?
- 1,265 filings are on EDGAR under the registrant records that have been BeOne Medicines Ltd. American Depositary Shares, going back to 2015; 715 of them are insider ownership forms (Forms 3, 4, 5 and 144).